{"hands_on_practices": [{"introduction": "In clinical practice, receiving a positive lab result is a critical first step, but it doesn't tell the whole story. This exercise introduces Bayes' theorem, a fundamental tool in evidence-based medicine that allows you to formally update your clinical suspicion based on new data. By working through this problem, you will learn to calculate the post-test probability of disease, helping you to quantify the true diagnostic power of a test like CMV PCR and understand how likely it is that your patient actually has the infection [@problem_id:4625509].", "problem": "A hospitalized solid-organ transplant recipient is evaluated for suspected active cytomegalovirus (CMV) infection. The attending physician estimates a pretest probability of active CMV infection of $0.20$ based on epidemiology in similar patients and the patient’s clinical presentation. A laboratory test is performed: cytomegalovirus deoxyribonucleic acid (DNA) detection by polymerase chain reaction (PCR). For the clinical definition of “active CMV infection” used in this unit, the PCR assay has sensitivity $0.97$ for detecting true active infection and specificity $0.94$ for correctly returning a negative result in the absence of active infection. The patient’s PCR result is positive.\n\nUsing only the fundamental definitions of sensitivity and specificity together with Bayes’ theorem from probability theory, derive the appropriate expression for the post-test probability of active CMV infection given a positive test, and then compute its value for the parameters provided. Express your final probability as a decimal fraction and round your answer to four significant figures.", "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It provides a standard scenario in medical diagnostics that can be rigorously analyzed using probability theory. All necessary data are provided, and there are no internal contradictions or ambiguities. The problem is therefore valid for solution.\n\nThe task is to derive an expression for the post-test probability of active cytomegalovirus (CMV) infection given a positive test result, and then to compute its numerical value. This requires the application of Bayes’ theorem using the fundamental definitions of sensitivity and specificity.\n\nLet us define the following events:\n- $D$: The event that the patient has an active CMV infection (Disease is present).\n- $D^c$: The event that the patient does not have an active CMV infection (Disease is absent).\n- $T^+$: The event that the laboratory test result is positive.\n- $T^-$: The event that the laboratory test result is negative.\n\nFrom the problem statement, we can extract the following probabilities:\n1.  The pretest probability of active CMV infection is the prior probability of the disease, $P(D)$.\n    $$P(D) = 0.20$$\n    The prior probability of not having the disease is therefore:\n    $$P(D^c) = 1 - P(D) = 1 - 0.20 = 0.80$$\n\n2.  The sensitivity of the test is the probability of a positive result given that the disease is present, $P(T^+|D)$.\n    $$\\text{Sensitivity} = P(T^+|D) = 0.97$$\n\n3.  The specificity of the test is the probability of a negative result given that the disease is absent, $P(T^-|D^c)$.\n    $$\\text{Specificity} = P(T^-|D^c) = 0.94$$\n    From this, we can determine the probability of a false positive, which is the probability of a positive test result given that the disease is absent, $P(T^+|D^c)$.\n    $$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - 0.94 = 0.06$$\n\nThe quantity to be calculated is the post-test probability of active CMV infection given a positive test result. This is the conditional probability $P(D|T^+)$.\n\nWe will use Bayes’ theorem, which states:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)}$$\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result. It can be calculated using the law of total probability by considering the two mutually exclusive scenarios in which a positive result can occur: a true positive (patient has the disease) and a false positive (patient does not have the disease).\n$$P(T^+) = P(T^+|D) P(D) + P(T^+|D^c) P(D^c)$$\n\nSubstituting this expansion of $P(T^+)$ into Bayes’ theorem, we arrive at the full expression for the post-test probability:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+|D) P(D) + P(T^+|D^c) P(D^c)}$$\n\nThis is the derived expression in terms of fundamental conditional probabilities. We can also express it in terms of sensitivity, specificity, and pretest probability (prevalence, denoted as $p$):\nLet $p = P(D)$.\nLet $\\text{sens} = P(T^+|D)$.\nLet $\\text{spec} = P(T^-|D^c)$.\nThen $P(D^c) = 1-p$ and $P(T^+|D^c) = 1-\\text{spec}$.\nThe expression becomes:\n$$P(D|T^+) = \\frac{(\\text{sens}) \\times p}{(\\text{sens}) \\times p + (1 - \\text{spec}) \\times (1-p)}$$\n\nNow, we compute the numerical value by substituting the given parameters:\n$$P(D|T^+) = \\frac{0.97 \\times 0.20}{0.97 \\times 0.20 + (1 - 0.94) \\times (1 - 0.20)}$$\nFirst, we calculate the terms in the expression:\n- The numerator (the probability of a true positive):\n  $$P(T^+|D) P(D) = 0.97 \\times 0.20 = 0.194$$\n- The probability of a false positive:\n  $$P(T^+|D^c) P(D^c) = 0.06 \\times 0.80 = 0.048$$\n\nThe total probability of a positive test, $P(T^+)$, is the sum of these two probabilities:\n$$P(T^+) = 0.194 + 0.048 = 0.242$$\n\nFinally, we compute the ratio to find the post-test probability:\n$$P(D|T^+) = \\frac{0.194}{0.242}$$\n$$P(D|T^+) \\approx 0.80165289...$$\n\nThe problem requires the answer to be rounded to four significant figures. The fifth significant figure is $5$, so we round up the fourth digit.\n$$P(D|T^+) \\approx 0.8017$$", "answer": "$$\\boxed{0.8017}$$", "id": "4625509"}, {"introduction": "Diagnosing Cytomegalovirus disease, particularly in complex transplant recipients, is rarely as simple as a single positive test. This case-based problem challenges you to move beyond one data point and synthesize a complete clinical picture, weighing evidence from histology, antigen detection, and viral load measurements. This practice hones your critical thinking, teaching you to differentiate true tissue-invasive disease from benign viral detection or sample contamination, which is a crucial skill for avoiding both under-treatment and over-treatment [@problem_id:4625554].", "problem": "A transplant medicine team evaluates two immunosuppressed patients for suspected Cytomegalovirus (CMV) disease. The team aims to use first-principles reasoning to distinguish contamination from true tissue-invasive CMV and to correctly interpret tissue CMV Polymerase Chain Reaction (PCR) positivity relative to plasma viremia.\n\nFundamental base to use:\n- CMV is a betaherpesvirus that establishes latency in leukocytes and can reactivate with tissue tropism (for example, gastrointestinal mucosa, retina, lung). Tissue-invasive disease is classically defined by a compatible clinical syndrome together with histopathologic evidence of viral cytopathic effect (for example, large cells with intranuclear inclusions) or antigen detection in tissue by Immunohistochemistry (IHC).\n- Polymerase Chain Reaction (PCR) detects CMV deoxyribonucleic acid (DNA) and has high analytic sensitivity; however, detection of CMV DNA alone does not distinguish latent genomes from actively replicating virus. Quantitative CMV PCR in plasma (cell-free) reflects systemic viremia and correlates with the intensity of replication and risk of dissemination, but absence of viremia does not exclude localized tissue disease.\n- Tissue biopsy specimens may be contaminated by blood and resident leukocytes; because CMV latency occurs in leukocytes, tissue CMV PCR can yield low-level positivity due to contamination or latent cell-associated DNA despite absence of true tissue invasion.\n\nScenario $1$: A patient who received a kidney transplant presents with watery diarrhea. Colonoscopic biopsies show chronic inflammation but no classic CMV cytopathic changes. Tissue CMV quantitative PCR returns $8 \\times 10^2$ copies per $\\mu$g DNA. CMV IHC is negative. The specimen is noted to be “bloody” with abundant erythrocytes on the requisition. Plasma CMV quantitative PCR is $<200$ International Units (IU)/mL (below the assay’s lower limit of quantification), and whole-blood CMV PCR is not performed.\n\nScenario $2$: A hematopoietic stem cell transplant recipient presents with odynophagia. Esophageal biopsy reveals cells with intranuclear inclusions consistent with CMV, and CMV IHC is positive. Tissue CMV quantitative PCR is $3 \\times 10^5$ copies per $\\mu$g DNA. Plasma CMV quantitative PCR is $2 \\times 10^4$ IU/mL.\n\nWhich single statement best reflects correct clinical interpretation consistent with the fundamental principles above?\n\nA. In Scenario $1$, low-level tissue CMV PCR positivity with negative CMV IHC and absent plasma viremia in a bloody biopsy most likely reflects contamination or latent cell-associated CMV DNA rather than tissue-invasive disease; definitive diagnosis of tissue-invasive CMV requires histopathology or antigen detection with compatible symptoms, whereas in Scenario $2$ the concordant histology, positive CMV IHC, high tissue CMV load, and elevated plasma viremia support true tissue-invasive disease.\n\nB. Any positive tissue CMV PCR, regardless of histology or plasma results, definitively indicates tissue-invasive CMV and mandates antiviral therapy in both scenarios.\n\nC. Plasma CMV viremia must be present to diagnose tissue-invasive CMV; therefore Scenario $1$ excludes tissue-invasive disease while Scenario $2$ proves it solely because plasma viremia is detected.\n\nD. Tissue CMV PCR is less sensitive than histology; therefore a negative CMV IHC in Scenario $1$ with a positive tissue CMV PCR proves active replication without cytopathic effect and should be treated as tissue-invasive disease.\n\nE. In Scenario $1$, the absence of plasma viremia makes blood contamination impossible, so tissue CMV PCR positivity necessarily represents localized tissue-invasive CMV; in Scenario $2$, tissue CMV PCR is unnecessary for diagnosis if plasma viremia exceeds $1 \\times 10^4$ IU/mL.", "solution": "## Problem Validation\n\n### Step 1: Extract Givens\n\n**Fundamental Base:**\n*   Cytomegalovirus (CMV) is a betaherpesvirus establishing latency in leukocytes.\n*   Reactivation can occur with tissue tropism.\n*   The definition of tissue-invasive disease is a compatible clinical syndrome plus one of the following:\n    *   Histopathologic evidence of viral cytopathic effect (e.g., large cells with intranuclear inclusions).\n    *   Antigen detection in tissue by Immunohistochemistry (IHC).\n*   Polymerase Chain Reaction (PCR) detects CMV deoxyribonucleic acid (DNA) with high analytic sensitivity.\n*   CMV DNA detection by PCR does not distinguish latent genomes from actively replicating virus.\n*   Quantitative CMV PCR in plasma (cell-free) reflects systemic viremia and correlates with replication intensity and dissemination risk.\n*   Absence of plasma viremia does not rule out localized tissue disease.\n*   Tissue biopsy specimens can be contaminated by blood and resident leukocytes.\n*   Low-level positive tissue CMV PCR can result from contamination or latent cell-associated DNA, not necessarily true tissue invasion.\n\n**Scenario 1:**\n*   Patient: Kidney transplant recipient.\n*   Syndrome: Watery diarrhea.\n*   Biopsy location: Colon.\n*   Histopathology: Chronic inflammation, no classic CMV cytopathic changes.\n*   Tissue CMV quantitative PCR: $8 \\times 10^2$ copies per $\\mu$g DNA.\n*   CMV IHC: Negative.\n*   Specimen quality note: \"bloody\" with abundant erythrocytes.\n*   Plasma CMV quantitative PCR: $<200$ International Units (IU)/mL (below lower limit of quantification).\n*   Whole-blood CMV PCR: Not performed.\n\n**Scenario 2:**\n*   Patient: Hematopoietic stem cell transplant recipient.\n*   Syndrome: Odynophagia.\n*   Biopsy location: Esophagus.\n*   Histopathology: Cells with intranuclear inclusions consistent with CMV.\n*   CMV IHC: Positive.\n*   Tissue CMV quantitative PCR: $3 \\times 10^5$ copies per $\\mu$g DNA.\n*   Plasma CMV quantitative PCR: $2 \\times 10^4$ IU/mL.\n\n**Question:**\n*   Which single statement best reflects correct clinical interpretation consistent with the fundamental principles?\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the required criteria:\n\n*   **Scientifically Grounded:** The problem is firmly rooted in established principles of medical microbiology and infectious disease diagnostics concerning CMV in immunocompromised hosts. The concepts of latency, viremia, tissue-invasive disease, and the specific roles and limitations of diagnostic tests (PCR, IHC, histology) are all standard and accurately represented.\n*   **Well-Posed:** The problem provides two distinct clinical scenarios with a comprehensive set of diagnostic data. The question asks for an interpretation based on a clearly defined set of \"Fundamental base\" principles. This structure allows for a unique, stable, and meaningful solution to be derived by applying the given rules to the given data.\n*   **Objective:** The problem is described using precise, objective clinical and laboratory terminology (e.g., \"intranuclear inclusions,\" \"negative CMV IHC,\" quantitative PCR values). There are no subjective or opinion-based statements in the problem setup.\n\nThe problem does not exhibit any of the defined flaws. It is not scientifically unsound, non-formalizable, incomplete, unrealistic, ill-posed, or trivial. The scenarios presented are classic and realistic teaching cases in transplant medicine.\n\n### Step 3: Verdict and Action\nThe problem is valid. A full solution will be derived.\n\n## Solution Derivation\n\nThe task is to apply the provided fundamental principles to interpret the two clinical scenarios.\n\n**Analysis of Scenario 1:**\n\n1.  **Clinical Syndrome:** The patient has watery diarrhea, which is a symptom compatible with CMV colitis.\n2.  **Definitive Diagnostic Criteria for Tissue-Invasive Disease:** The principles state that definitive diagnosis requires either histopathologic evidence (cytopathic effect) or positive tissue antigen detection (IHC).\n3.  **Applying the Criteria:** In this scenario, colonoscopic biopsies show no CMV cytopathic changes, and CMV IHC is negative. Therefore, the definitive criteria for tissue-invasive CMV disease are **not met**.\n4.  **Interpreting the PCR Result:** The tissue CMV PCR is positive at a low level ($8 \\times 10^2$ copies per $\\mu$g DNA). The principles explicitly address this situation: \"PCR...detection of CMV DNA alone does not distinguish latent genomes from actively replicating virus,\" and \"tissue CMV PCR can yield low-level positivity due to contamination or latent cell-associated DNA despite absence of true tissue invasion.\"\n5.  **Synthesizing with Other Data:** The specimen was noted to be \"bloody.\" The principles state that CMV establishes latency in leukocytes, which are present in blood. Therefore, blood contamination of the biopsy specimen is a highly plausible explanation for the low-level positive PCR result. Furthermore, plasma CMV PCR is negative ($<200$ IU/mL), indicating an absence of significant systemic viral replication. While the absence of viremia does not absolutely exclude localized disease, it makes it less likely and provides corroborating evidence against widespread or intense viral replication.\n6.  **Conclusion for Scenario 1:** The combination of negative histology and IHC, a \"bloody\" specimen, absent plasma viremia, and a low-titer positive tissue PCR result strongly suggests that the finding is due to contamination by latently infected leukocytes in the blood, rather than true tissue-invasive CMV colitis.\n\n**Analysis of Scenario 2:**\n\n1.  **Clinical Syndrome:** The patient has odynophagia (painful swallowing), which is a classic symptom of CMV esophagitis.\n2.  **Definitive Diagnostic Criteria for Tissue-Invasive Disease:** The principles require histopathology or positive IHC.\n3.  **Applying the Criteria:** In this scenario, the esophageal biopsy meets **both** criteria: it reveals \"cells with intranuclear inclusions consistent with CMV\" (the classic \"owl's eye\" cytopathic effect) and CMV IHC is positive. Therefore, the diagnosis of tissue-invasive CMV disease is definitively established.\n4.  **Interpreting Supporting Data:** The tissue CMV quantitative PCR is very high ($3 \\times 10^5$ copies per $\\mu$g DNA), which is consistent with active, high-level viral replication within the esophageal tissue. The plasma CMV quantitative PCR is also significantly elevated ($2 \\times 10^4$ IU/mL), indicating systemic viremia, which often accompanies and reflects the severity of tissue-invasive disease.\n5.  **Conclusion for Scenario 2:** All data points are concordant and point to a clear diagnosis of true tissue-invasive CMV esophagitis. The histopathology and IHC are diagnostic, and the high tissue and plasma viral loads confirm active, significant infection.\n\n## Option-by-Option Analysis\n\n**A. In Scenario $1$, low-level tissue CMV PCR positivity with negative CMV IHC and absent plasma viremia in a bloody biopsy most likely reflects contamination or latent cell-associated CMV DNA rather than tissue-invasive disease; definitive diagnosis of tissue-invasive CMV requires histopathology or antigen detection with compatible symptoms, whereas in Scenario $2$ the concordant histology, positive CMV IHC, high tissue CMV load, and elevated plasma viremia support true tissue-invasive disease.**\n*   This statement accurately summarizes the analysis of both scenarios derived from the fundamental principles. It correctly identifies the likely cause of the PCR result in Scenario $1$ (contamination/latency) by synthesizing all the negative findings and the bloody nature of the specimen. It correctly states the gold standard for diagnosis from the principles. It then correctly identifies the concordant, definitive evidence for true tissue-invasive disease in Scenario $2$.\n*   **Verdict: Correct**\n\n**B. Any positive tissue CMV PCR, regardless of histology or plasma results, definitively indicates tissue-invasive CMV and mandates antiviral therapy in both scenarios.**\n*   This statement directly contradicts the provided principles, which explicitly warn that \"detection of CMV DNA alone does not distinguish latent genomes from actively replicating virus\" and that low-level positivity can be due to \"contamination or latent cell-associated DNA.\" Scenario $1$ is a perfect illustration of this caveat.\n*   **Verdict: Incorrect**\n\n**C. Plasma CMV viremia must be present to diagnose tissue-invasive CMV; therefore Scenario $1$ excludes tissue-invasive disease while Scenario $2$ proves it solely because plasma viremia is detected.**\n*   The premise \"Plasma CMV viremia must be present\" is false. The principles state the opposite: \"absence of viremia does not exclude localized tissue disease.\" The conclusion for Scenario $2$ is also flawed; the diagnosis is proven by histopathology and IHC, not \"solely\" by the presence of viremia.\n*   **Verdict: Incorrect**\n\n**D. Tissue CMV PCR is less sensitive than histology; therefore a negative CMV IHC in Scenario $1$ with a positive tissue CMV PCR proves active replication without cytopathic effect and should be treated as tissue-invasive disease.**\n*   The premise \"Tissue CMV PCR is less sensitive than histology\" is false. The principles state PCR has \"high analytic sensitivity.\" In reality, PCR is significantly more sensitive than histology or IHC, which is why it can detect latent or contaminating DNA that is not associated with tissue injury. The conclusion drawn from this false premise is therefore invalid.\n*   **Verdict: Incorrect**\n\n**E. In Scenario $1$, the absence of plasma viremia makes blood contamination impossible, so tissue CMV PCR positivity necessarily represents localized tissue-invasive CMV; in Scenario $2$, tissue CMV PCR is unnecessary for diagnosis if plasma viremia exceeds $1 \\times 10^4$ IU/mL.**\n*   The first part of the statement contains a critical logical flaw. Plasma is the acellular fluid portion of blood. CMV latency is in leukocytes (cells). It is entirely possible to have CMV-positive leukocytes in the circulation without having cell-free CMV DNA (viremia) in the plasma, especially at low levels. Thus, the absence of plasma viremia does not make blood contamination impossible. The second part is also problematic; while a high plasma viremia is a strong indicator, the provided \"fundamental base\" defines the diagnosis of *tissue-invasive disease* by tissue-based findings (histology/IHC), not by a plasma viral load threshold.\n*   **Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4625554"}, {"introduction": "Once the decision to treat a patient is made, effective therapy hinges on administering the correct drug dose. This is especially critical for renally-cleared drugs like valganciclovir in patients with impaired kidney function, a common scenario in the transplant population. This exercise provides hands-on practice in clinical pharmacokinetics, where you will use a patient's specific physiological data and the Cockcroft-Gault equation to tailor a standard drug regimen, a vital skill for maximizing efficacy while minimizing the risk of toxicity [@problem_id:4625445].", "problem": "A 68-year-old male with cytomegalovirus (CMV) retinitis is beginning oral valganciclovir maintenance therapy. To maintain equivalent systemic exposure to a standard patient with normal renal function, the regimen is chosen such that the area under the plasma concentration–time curve (AUC) is matched between the two patients under the assumption of linear pharmacokinetics, constant oral bioavailability, and identical dosing intervals. The standard per-dose amount used in patients with normal renal function is $900$ mg once daily, and the reference creatinine clearance for a normal adult is $100$ mL/min. The patient’s serum creatinine is $2.2$ mg/dL, and his actual body weight is $75$ kg.\n\nUse the Cockcroft–Gault equation for males to estimate creatinine clearance, where the creatinine clearance $\\text{CrCl}$ in mL/min is given by\n$$\n\\text{CrCl}=\\frac{(140-\\text{age})\\times \\text{weight}}{72\\times \\text{SCr}},\n$$\nwith $\\text{age}$ in years, $\\text{weight}$ in kilograms, and serum creatinine $\\text{SCr}$ in mg/dL. Then, using appropriate first principles of linear pharmacokinetics and exposure matching, compute the adjusted per-dose amount of valganciclovir in milligrams for this patient. Express your final dose in mg and round your answer to three significant figures.", "solution": "The problem statement is evaluated for validity prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n- Patient age: $68$ years\n- Diagnosis: Cytomegalovirus (CMV) retinitis\n- Drug: Oral valganciclovir maintenance therapy\n- Pharmacokinetic objective: Maintain equivalent systemic exposure to a standard patient, meaning the area under the plasma concentration-time curve (AUC) is matched ($\\text{AUC}_{\\text{patient}} = \\text{AUC}_{\\text{standard}}$).\n- Assumptions: Linear pharmacokinetics, constant oral bioavailability ($F$), and identical dosing intervals ($\\tau$).\n- Standard dose ($D_{\\text{ref}}$): $900$ mg once daily\n- Reference creatinine clearance ($\\text{CrCl}_{\\text{ref}}$): $100$ mL/min\n- Patient's serum creatinine ($\\text{SCr}$): $2.2$ mg/dL\n- Patient's actual body weight (weight): $75$ kg\n- Equation for creatinine clearance ($\\text{CrCl}$) for males (Cockcroft–Gault): $\\text{CrCl} = \\frac{(140 - \\text{age}) \\times \\text{weight}}{72 \\times \\text{SCr}}$\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is grounded in established principles of clinical pharmacokinetics. Dose adjustment based on renal function is a standard and critical practice for drugs eliminated by the kidneys, such as ganciclovir (the active metabolite of valganciclovir). The Cockcroft–Gault equation is a widely used, albeit classic, method for estimating creatinine clearance. The patient data provided are physiologically plausible for an elderly individual with compromised renal function.\n2.  **Well-Posed**: The problem is well-posed. It provides all necessary data (patient demographics, lab values, reference dose and clearance, and the required formula) to calculate a unique solution. The objective (AUC matching) and the assumptions (linear PK, constant F) provide a clear path to the solution.\n3.  **Objective**: The problem is stated using precise, objective, and quantitative language. It is free from subjective claims or ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and objective. It is deemed **valid**. A solution will be furnished.\n\n### Solution Derivation\nThe primary objective is to match the systemic exposure, as measured by the area under the plasma concentration–time curve ($\\text{AUC}$), between the patient and a reference individual with normal renal function.\n\nFor a drug administered orally under steady-state conditions with linear pharmacokinetics, the $\\text{AUC}$ over a dosing interval, $\\tau$, is given by:\n$$\n\\text{AUC} = \\frac{F \\times D}{\\text{CL}}\n$$\nwhere $F$ is the oral bioavailability, $D$ is the dose administered per interval, and $\\text{CL}$ is the total body clearance of the drug.\n\nThe condition for matched exposure is $\\text{AUC}_{\\text{pt}} = \\text{AUC}_{\\text{ref}}$, where 'pt' denotes the patient and 'ref' denotes the reference individual.\n$$\n\\frac{F_{\\text{pt}} \\times D_{\\text{pt}}}{\\text{CL}_{\\text{pt}}} = \\frac{F_{\\text{ref}} \\times D_{\\text{ref}}}{\\text{CL}_{\\text{ref}}}\n$$\nThe problem states to assume constant oral bioavailability ($F_{\\text{pt}} = F_{\\text{ref}}$) and identical dosing intervals. The term $F$ can thus be cancelled from both sides of the equation:\n$$\n\\frac{D_{\\text{pt}}}{\\text{CL}_{\\text{pt}}} = \\frac{D_{\\text{ref}}}{\\text{CL}_{\\text{ref}}}\n$$\nSolving for the patient's adjusted dose, $D_{\\text{pt}}$, yields:\n$$\nD_{\\text{pt}} = D_{\\text{ref}} \\times \\frac{\\text{CL}_{\\text{pt}}}{\\text{CL}_{\\text{ref}}}\n$$\nThis equation shows that the dose must be adjusted in direct proportion to the patient's clearance relative to the reference clearance.\n\nValganciclovir is a prodrug of ganciclovir, which is eliminated almost entirely by the kidneys. Therefore, its total body clearance ($\\text{CL}$) is directly proportional to the renal function, which can be estimated by the creatinine clearance ($\\text{CrCl}$). We can thus state that $\\text{CL} \\approx k \\times \\text{CrCl}$, where $k$ is a proportionality constant. The ratio of clearances can then be replaced by the ratio of creatinine clearances:\n$$\n\\frac{\\text{CL}_{\\text{pt}}}{\\text{CL}_{\\text{ref}}} = \\frac{k \\times \\text{CrCl}_{\\text{pt}}}{k \\times \\text{CrCl}_{\\text{ref}}} = \\frac{\\text{CrCl}_{\\text{pt}}}{\\text{CrCl}_{\\text{ref}}}\n$$\nSubstituting this ratio back into the dosing equation gives our final working formula:\n$$\nD_{\\text{pt}} = D_{\\text{ref}} \\times \\frac{\\text{CrCl}_{\\text{pt}}}{\\text{CrCl}_{\\text{ref}}}\n$$\nFirst, we must calculate the patient's creatinine clearance ($\\text{CrCl}_{\\text{pt}}$) using the Cockcroft–Gault equation provided.\nGiven:\n- $\\text{age} = 68$ years\n- $\\text{weight} = 75$ kg\n- $\\text{SCr} = 2.2$ mg/dL\n$$\n\\text{CrCl}_{\\text{pt}} = \\frac{(140 - \\text{age}) \\times \\text{weight}}{72 \\times \\text{SCr}} = \\frac{(140 - 68) \\times 75}{72 \\times 2.2}\n$$\n$$\n\\text{CrCl}_{\\text{pt}} = \\frac{72 \\times 75}{72 \\times 2.2} = \\frac{75}{2.2}\n$$\n$$\n\\text{CrCl}_{\\text{pt}} \\approx 34.0909... \\text{ mL/min}\n$$\nNow, we can calculate the adjusted dose $D_{\\text{pt}}$ using the known values:\n- $D_{\\text{ref}} = 900$ mg\n- $\\text{CrCl}_{\\text{ref}} = 100$ mL/min\n- $\\text{CrCl}_{\\text{pt}} = \\frac{75}{2.2}$ mL/min\n$$\nD_{\\text{pt}} = 900 \\text{ mg} \\times \\frac{\\frac{75}{2.2} \\text{ mL/min}}{100 \\text{ mL/min}}\n$$\n$$\nD_{\\text{pt}} = 900 \\times \\frac{75}{2.2 \\times 100} = 9 \\times \\frac{75}{2.2}\n$$\n$$\nD_{\\text{pt}} = \\frac{675}{2.2} \\approx 306.8181... \\text{ mg}\n$$\nThe problem requires the final answer to be rounded to three significant figures. The first three significant figures are $3$, $0$, and $6$. The fourth digit is $8$, which is $5$ or greater, so we round up the third digit.\n$$\nD_{\\text{pt}} \\approx 307 \\text{ mg}\n$$\nThe adjusted per-dose amount of valganciclovir for this patient is $307$ mg.", "answer": "$$\\boxed{307}$$", "id": "4625445"}]}